Immuno-Biological Laboratories Co., Ltd. (4570.T) Comparison with companies in other sectors?

Immuno-Biological Laboratories Co., Ltd. has a share price of 9.31M. You can analyze Immuno-Biological Laboratories Co., Ltd. (4570.T) competitors across different market sectors through stock heatmaps.

What are 4570.T's NET and operating margins?

Immuno-Biological Laboratories Co., Ltd. (4570.T) operating margin is around 0.22, and net profit margin is approximately 0.26 as of the latest reports.

In what way does 4570.T's earnings per share (EPS) trend reflect its financial momentum?

Immuno-Biological Laboratories Co., Ltd. (4570.T) EPS is 26.72 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Immuno-Biological Laboratories Co., Ltd. is 18.75, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Immuno-Biological Laboratories Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Immuno-Biological Laboratories Co., Ltd. like P/E which is 18.76, P/B which is 3.08, and PEG which is -1.13. Compare them with sector averages to evaluate if the stock is priced fairly.

Immuno-Biological Laboratories Co., Ltd.

4570.T•JPX

Healthcare

Biotechnology

¥504.00

¥-5.00(-0.98%)

Immuno-Biological Laboratories Co., Ltd. (4570.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$26.72

P/E Ratio

18.75

ROE

0.18%

Net Margin

0.26%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.67B

Shares OutstandingTotal number of shares issued

$9.31M

Book Value/ShareNet worth per share

$162.60

Revenue/ShareAnnual revenue per share

$104.09

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$26.72

Net MarginNet income as percentage of revenue

25.65%

Operating MarginOperating income as percentage of revenue

21.63%

ROEReturn on shareholders' equity

17.88%

ROAReturn on total assets

13.48%

ROCEReturn on capital employed

13.40%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$88.66

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 4570.TFinancial Ratios Analysis details for 4570.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 4570.TSector Benchmarking details for 4570.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Immuno-Biological Laboratories Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Immuno-Biological Laboratories Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Immuno-Biological Laboratories Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Immuno-Biological Laboratories Co., Ltd.

For Immuno-Biological Laboratories Co., Ltd., essential financial indicators include EPS 26.72, PE 18.75, and ROE 0.18. These key ratios reveal insights into Immuno-Biological Laboratories Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Immuno-Biological Laboratories Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Immuno-Biological Laboratories Co., Ltd.

Metrics like Net Margin 25.65% and ROA 13.48% shed light on how well Immuno-Biological Laboratories Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Immuno-Biological Laboratories Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Immuno-Biological Laboratories Co., Ltd.

Using ratios such as P/B Ratio 3.08 and PEG Ratio -1.13, investors can assess whether Immuno-Biological Laboratories Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Immuno-Biological Laboratories Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Immuno-Biological Laboratories Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 0.13 and Cash Flow -, provide a snapshot of Immuno-Biological Laboratories Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Immuno-Biological Laboratories Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Immuno-Biological Laboratories Co., Ltd.

Investing in Immuno-Biological Laboratories Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Immuno-Biological Laboratories Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;